Sample map
One indication,
one page.
This is the format: a market map you can screen by stage and science, and a company dossier assembled from cited events. The data below is a fictional illustration. The real map is built only from sourced facts.
Cardiometabolic: private companies by stage
Plate 04 · illustrativeSmall molecule
4 financed this year · 2 stealth syndicates detected
Gene therapy
1 clinical hold in adjacent target class
Peptide / GLP-adjacent
Syndicate overlap with 3 top-decile funds
RNA
2 licensing options signed since January
Small molecule
3 readouts due within two quarters
Heart failure
$430M raised across last 4 rounds
Lipid disorders
1 crossover round closed pre-readout
Devices + drug
M&A interest reported in trade press
Company dossier: Meridian Cardio (fictional)
Assembled from cited eventsClinical-stage cardiometabolic company; lead peptide program in heart failure with preserved ejection fraction (HFpEF).
- Latest round
- $184M Series B, led by a top-decile fund
- ✓ Trade-press financing announcement
- Lead program
- Phase 2, HFpEF, primary endpoint met
- ✓ ClinicalTrials.gov status change
- Mechanism
- GLP-adjacent peptide agonist
- ✓ Company pipeline page
- Syndicate
- 6 investors; 4 recurring co-investors across the round
- ✓ Cross-checked press releases
- Partnership status
- No large-pharma partner on the lead asset
- ✓ Absence confirmed across sources
Every row above would, in the product, link to the source document and the verbatim snippet it was extracted from.
Want this for your indication?
Tell us what you cover and we'll open your view of the map.